FDA Backlog Keeps Generics From Coming To Market

FDA Backlog Keeps Generics From Coming To Market
FDA Backlog Keeps Generics From Coming To Market

In October 2015, there were as many as 3,000 generics waiting to be approved by the Food and Drug Administration. FDA underfunding may explain it in part. So might incomplete information on applications by their manufacturers as the FDA claims. But, whatever the reason, the result is that we end up paying high drug prices, (though some generic drug prices are sky high.)

Generics can cost as little as 20 percent of what brand-name drugs cost; they can also cost a lot more.

FDA: Around 8 out of 10 prescriptions are for generics but they account for less than 30 percent of our drug spending.

Read the full article about FDA and Generics at JustCareUSA.org →

Diane Archer
JustCareUSA.org